Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Given Average Rating of “Buy” by Analysts

by · The Cerbat Gem

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH – Get Free Report) has been given a consensus rating of “Buy” by the seven ratings firms that are covering the company, MarketBeat reports. Five analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $10.00.

Several brokerages have commented on RVPH. Roth Capital upgraded shares of Reviva Pharmaceuticals to a “strong-buy” rating in a research note on Friday, January 10th. Roth Mkm initiated coverage on shares of Reviva Pharmaceuticals in a research report on Friday, January 10th. They set a “buy” rating and a $7.00 target price for the company. HC Wainwright cut their price target on Reviva Pharmaceuticals from $14.00 to $11.00 and set a “buy” rating on the stock in a research report on Wednesday, January 22nd. Maxim Group raised Reviva Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 price objective for the company in a report on Friday, January 10th. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $8.00 target price on shares of Reviva Pharmaceuticals in a report on Thursday.

View Our Latest Stock Report on RVPH

Reviva Pharmaceuticals Price Performance

NASDAQ RVPH opened at $0.86 on Monday. The company has a market cap of $39.97 million, a price-to-earnings ratio of -0.77 and a beta of 0.05. The stock’s fifty day moving average price is $1.00 and its 200 day moving average price is $1.38. Reviva Pharmaceuticals has a 1 year low of $0.49 and a 1 year high of $4.28.

Reviva Pharmaceuticals (NASDAQ:RVPH – Get Free Report) last announced its quarterly earnings data on Monday, March 31st. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.07. Research analysts expect that Reviva Pharmaceuticals will post -0.97 earnings per share for the current year.

Hedge Funds Weigh In On Reviva Pharmaceuticals

Large investors have recently bought and sold shares of the business. Tang Capital Management LLC purchased a new stake in shares of Reviva Pharmaceuticals in the fourth quarter valued at approximately $308,000. Cornerstone Select Advisors LLC acquired a new position in Reviva Pharmaceuticals during the fourth quarter worth $32,000. Ameriprise Financial Inc. purchased a new position in Reviva Pharmaceuticals during the fourth quarter valued at $84,000. Tower Research Capital LLC TRC grew its position in shares of Reviva Pharmaceuticals by 848.8% in the fourth quarter. Tower Research Capital LLC TRC now owns 26,775 shares of the company’s stock valued at $48,000 after purchasing an additional 23,953 shares during the period. Finally, XTX Topco Ltd acquired a new stake in shares of Reviva Pharmaceuticals in the fourth quarter valued at about $45,000. Institutional investors and hedge funds own 63.18% of the company’s stock.

About Reviva Pharmaceuticals

(Get Free Report

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.

Featured Stories